Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214773 · ClinicalTrials.gov registry record
Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)
A clinical trial, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- 237
- Enrollment target
NCT00214773 is a clinical trial that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 237 participants.
The verdict
NCT00214773 has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- 237 participants
- Enrollment target
Study Summary
The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care based on aggregate data; to characterize the clinical response to long-term Naglazyme® (galsulfase) treatment; to further characterize the long-term safety of Naglazyme® treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2005-07 |
| Est. Completion | 2020-05-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00214773
The ClinicalTrials.gov registry entry for NCT00214773 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00214773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00214773 about?
NCT00214773 is a clinical study titled "Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)". The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing informatio...
What is the current status of trial NCT00214773?
This trial is currently completed. The enrollment target is 237 participants. The study started on 2005-07. Estimated completion is 2020-05-01.
Who is sponsoring clinical trial NCT00214773?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.